Researchers at Columbia demonstrated the first real-time brain-controlled hearing system that can identify which speaker a listener is focusing on in a noisy environment and automatically amplify that voice while suppressing others. "This breakthrough addresses the 'cocktail party effect,' a major limitation of conventional hearing aids, which often struggle to distinguish between overlapping conversations in noisy settings," reports Neuroscience News. From the report: In the new study, Columbia researchers teamed up with surgeons and their epilepsy patients who were undergoing brain surgery to better pinpoint the sources of their seizures. The hospital patients, who volunteered to be part of this study, already had electrodes implanted in their brains. [senior author Nima Mesgarani's] system used the electrodes to measure the brain activity of the patients as they focused on one of two overlapping conversations played simultaneously. The system then automatically detected which conversation a patient was paying attention to and adjusted the volume in real time, turning up that conversation while quieting the other. For one volunteer, the experience of controlling the system with her brain was literally unbelievable. She accused the researchers of secretly adjusting the volumes. Others told stories about friends and family with hearing impairments who could benefit from such a technology. One person said: "It seems like science fiction." [...] The scientists developed real-time machine-learning algorithms that could examine the brainwaves and identify which conversation the patients were paying attention to. Once deployed, their system could rapidly deduce which conversation each listener was paying attention to and make it easier for them to hear it. This happened both when the researchers guided the subjects toward a particular conversation, and when the subjects chose freely, as would be necessary in a real-world conversation. "For this to work in real time, the system has to be very fast, accurate and stable for the experience to feel pleasant for the listener," Dr. Mesgarani said. The scientists found their new system correctly identified which conversation the volunteers paid attention to. This dramatically improved the intelligibility of the speech the volunteers focused on, reduced listening effort, and was consistently preferred by the volunteers when compared to conversations the system did not provide assistance with. One volunteer recalled her uncle, who had hearing problems. "Can you imagine if this technology existed in a world [where] ... he could access it? He might actually live a much more peaceful... life." The research has been published in Nature Neuroscience.

Read more of this story at Slashdot.

An anonymous reader quotes a report from the Guardian: Singing, painting or visiting a gallery or museum helps people age more slowly, according to the latest study to link taking an active interest in art and culture with improved health. The findings are the first to show that both participating in arts activities and attending events, such as viewing an exhibition, lead to people staying biologically younger. "These results demonstrate the health impact of the arts at a biological level. They provide evidence for arts and cultural engagement to be recognized as a health-promoting behavior in a similar way to exercise," said Prof Daisy Fancourt, the lead author of the research and the head of the social biobehavioral research group at University College London. However, slower aging does not necessarily mean someone will live longer. The "epigenetic clocks" used in the study to assess biological ageing are predictive of future morbidity and mortality, and previous studies have suggested a link between arts engagement and longer lifespan, but much more research would be needed to establish potential causal effects on longevity. Those who take part in artistic pursuits the most often slow the pace of their biological aging the most. Under one of the study's methods of assessment, those who did so at least weekly slowed their aging process by 4%, while monthly engagement led to it slowing by 3%. Similarly, another of the tests showed that those who undertook an arts activity at least once a week were on average a year younger biologically than those who rarely engaged in such pursuits. Those who exercised once a week were only six months younger by that measure. The benefit the arts confer on the pace at which people age is so dramatic that it is comparable to the difference between smokers and those who have given up smoking, the researchers say. The results, published in the journal Innovation in Aging, are based on blood test and survey response data from 3,556 adults taking part in the UK Household Longitudinal Study. It uses blood samples to estimate people's biological age and the pace at which they are ageing.

Read more of this story at Slashdot.

A small study found that a single 25mg dose of psilocybin produced measurable brain changes that were still visible a month later, along with reported improvements in psychological insight, wellbeing, and mental flexibility. The Guardian reports: Evidence for the changes came from specialized scans that measured the diffusion of water along nerve bundles in the brain. They suggested that some nerve tracts had become denser and more robust after the drug was taken. While the findings are preliminary, the scientists said the opposite was seen in ageing and dementia. "It's remarkable to see potential anatomical brain changes one month after a single dose of any drug," said Prof Robin Carhart-Harris, a neurologist at the University of California, San Francisco, and senior author on the study. "We don't yet know what these changes mean, but we do note that overall, people showed positive psychological changes in this study, including improved wellbeing and mental flexibility." [...] Writing in Nature Communications, the researchers describe another key finding. Those who had the largest spike in brain entropy after psilocybin were most likely to report deeper psychological insight and better wellbeing a month later, underlining the link between flexible thinking and improved mental health. "It suggests a psychobiological therapeutic action for psilocybin," said Carhart-Harris. Prof Alex Kwan, a neuroscientist at Cornell University in New York, said studies in mice had shown that psychedelics can rewire connections between nerves, a form of "plasticity" that could underlie their therapeutic effects. The big question is whether the same occurs in humans. "This study comes closer than most to addressing that question, by giving evidence of lasting changes in brain structure after psychedelic use," he said. But while the results were "exciting," the study involved a small number of people and DTI provides an indirect and limited view of brain connections, he said.

Read more of this story at Slashdot.

This week Bill Gates wrote a blog post about a special camera from medtech startup Remidio, which delivers high-resolution images of a patient's retina in seconds. The camera plugs into a phone running an AI system that watches for early signs of diabetes — all without needing a blood draw, eye dilation, or a dibetes specialist. It's already been used in 40 countries for more than 15 million patients. But that same hardware, with different software, can also flag the conditions that drive so many dangerous pregnancies. Gestational diabetes sharply increases the risk of pre-eclampsia [a spike in blood pressure during pregnancy responsible for half a million fetal deaths every year and 70,000 maternal deaths]... In most of rural sub-Saharan Africa or South Asia, it usually isn't screened for at all, because the standard test requires a lab. A retinal scan offers a different way in. Remidio's device is currently being used in India to screen pregnant women for conditions that drive stillbirth. And researchers are now adapting the same hardware to screen for anemia and hypertension, too... [S]mall, portable, affordable diagnostics in the hands of community health workers are exactly the kind of lever that can start to move a number that hasn't moved in a long time.

Read more of this story at Slashdot.

A new study from Harvard Medical School and Beth Israel Deaconess found that an OpenAI reasoning model outperformed experienced ER doctors at diagnosing and managing patient cases using messy, real-world emergency department records. Researchers say the results don't support replacing doctors, but they do suggest AI could meaningfully reshape clinical workflows if tested carefully in prospective trials. NPR reports: The researchers ran a series of experiments on the AI model to test its clinical acumen -- including actual cases like the lupus patient who'd been previously treated at the emergency department at Beth Israel in Boston. The team graded how well the AI model could provide an accurate diagnosis at three moments in time, from the triage stage in the ER, up to being admitted into the hospital. Overall, AI outperformed two experienced physicians -- and did so with only the electronic health records and the limited information that had been available to the physicians at the time. "This is the big conclusion for me -- it works with the messy real-world data of the emergency department, " said Dr. Adam Rodman, a clinical researcher at Beth Israel and one of the study authors. "It works for making diagnoses in the real world." Other parts of the study focused on case reports published in the New England Journal of Medicine and clinical vignettes to suss out whether the AI model could meet well-established "benchmarks" and game out thorny diagnostic questions. "The model outperformed our very large physician baseline," said Raj Manrai, assistant professor of Biomedical Informatics at Harvard Medical School who was also part of the study. The authors emphasize the AI relied on text alone, while in real life, clinicians need to attend to many other inputs like images, sounds and nonverbal cues when diagnosing and treating a patient. The findings have been published Thursday in the journal Science.

Read more of this story at Slashdot.

An anonymous reader quotes a report from NBC News: The Food and Drug Administration on Friday granted a quick review of three experimental psychedelic drugs meant to treat major depression and post-traumatic stress disorder. It's the latest move by the Trump administration signaling a shift in policy toward treatments that also give users a high -- coming a day after the Justice Department said it would ease restrictions on state-licensed medical marijuana. UK-based biotech company Compass Pathways said Friday it has received an expedited review for its experimental form of synthetic psilocybin for treatment-resistant depression. In a press release the company cited two large, phase 3 studies that had "generated positive data." Usona Institute, headquartered in Wisconsin, also said it's received a voucher for its work with psilocybin to treat major depressive disorder. In an email, a Usona spokesperson said the company expects the review process to last one to two months after it submits its application. "The voucher expedites the timeline only; it does not alter scientific or regulatory standards," the spokesperson wrote. New York-based Transcend Therapeutics has also been granted a priority review voucher for its experimental drug methylone for PTSD, Blake Mandell, the company's chief executive officer, said. "There's a battle still raging in their mind that we don't fully understand biochemically," FDA Commissioner Marty Makary said. "When you see something that looks promising for a community that is suffering with mental health illness, despair and suicidal ideation, you can't help but recognize that." Makary told NBC News that with the priority voucher program, the agency could potentially approve the first psychedelic drug by the end of summer.

Read more of this story at Slashdot.

Apple's Vision Pro has been used in what's described as the world's first cataract surgery performed with the headset. MacRumors reports: [New York opthalmologist] Dr. Eric Rosenberg of SightMD completed the initial procedure in October 2025 and has since performed hundreds of additional cases using ScopeXR, a surgical platform he co-developed for Apple's mixed reality device. ScopeXR streams live feeds from 3D digital surgical microscopes directly into the Vision Pro, which lets the surgeon view the operative field in stereoscopic 3D while overlaying preoperative diagnostic data. The platform also supports real-time remote collaboration, allowing surgeons to virtually join procedures and see exactly what the operating surgeon sees. "We are now able to bring the world's best surgeon into any operating room, at any hour, from anywhere on the planet," said Dr. Rosenberg in a company press release. "From residents performing their first cases to surgeons facing unexpected complications, this technology democratizes access to expertise and that will save vision."

Read more of this story at Slashdot.

An anonymous reader quotes a report from NPR: The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf. The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as a milestone in the quest to treat hearing loss. "It's the first time in history there's a new drug for hearing loss," says Zheng-Yi Chen, an associate scientist at Mass Eye and Ear in Boston who was not involved in the development of the therapy approved by the FDA Thursday. But his research team reported very promising results with a similar approach Wednesday. "I think it's an historical event, a landmark, a great development for the whole field," he says of the approval. [...] The FDA's decision was based on the results from the treatment of 20 patients born with a defective version of a gene known as OTOF, which is necessary to transmit sound from the ears to the brain. Doctors infused billions of adeno-associated viruses into the patients' ears by making a small incision behind the ear to open a small hole in the skull. The viruses carried a healthy version of the OTOF gene that had been split in half to fit inside the virus. The gene provides instructions to make the otoferlin protein, which is necessary for hair cells in the inner ear to transmit sound to the brain. Most of the patients began to hear for the first time within weeks, with the quality of their hearing improving over the following months, according to [Regeneron Pharmaceuticals, which developed the gene therapy and plans to offer it for free in the U.S. It should be available within weeks.]. The amount of hearing patients gained varied, but 80% achieved at least some significant hearing restoration and 42% ended up with normal hearing, which included the ability to hear whispers, Regeneron says. The hearing ability has lasted at least two years so far. The treatment can only help patients with the very rare form of deafness that Smith was born with, which only affects about 50 children each year in the U.S. But similar gene therapies are showing promise for other forms of genetic deafness. And researchers hope someday gene therapy may help with common types of hearing loss, like from aging and loud noise.

Read more of this story at Slashdot.

A 63-year-old man in Norway appears to be cured of HIV after receiving a stem cell transplant from his brother, who turned out to have a rare mutation that makes immune cells resistant to HIV. "Four years after the transplant, and two years after the man stopped antiretroviral therapy, he still appears to be free of the infection," reports Gizmodo. From the report: According to the report, the man was first diagnosed with myelodysplastic syndrome, a type of cancer that weakens blood cell production from bone marrow, in 2018. Though he seemed to initially respond to treatment, the cancer returned after two years, and doctors decided to perform a stem cell transplant. Because the man also had HIV (diagnosed in 2006), the doctors were hoping to treat both conditions at once, though they knew their chances were low. Most of these cases have involved the use of stem cells taken from people with two copies of a particular mutation in their CCR5 gene, which regulates the CC5R receptor on white blood cells. This mutation, named CCR5-delta 32, makes immune cells naturally resistant to infection from strains of HIV-1 (the most common type of the virus). However, only about 1% of the population carries two copies of the mutation. After initial screening failed to find someone who both possessed the mutation and had compatible bone marrow, the doctors decided to move ahead with the man's brother, who was already known to have compatible bone marrow. But to everyone's surprise, testing on the day of the transplant showed that the brother also had the mutation. Though the man did experience some complications from the procedure, his body successfully started to produce new blood cells with the mutation. The doctors decided to take him off antiretroviral medication two years after the transplant. And in the two years since then, regular follow-up tests have failed to show any signs of the virus in his system. [...] According to AFP, there have only been roughly 10 cases worldwide involving an HIV cure through stem cell transplantation. This is the first to involve a family donor.

Read more of this story at Slashdot.

Plants, toads, and mushrooms "can all produce psychedelic substances," writes ScienceAlert. "And now their powers have been combined in one plant." [S]cientists have taken the genes these organisms use to make five natural psychedelics and introduced them into a tobacco plant ( Nicotiana benthamiana), which then produced all five compounds simultaneously. As interest grows in psychedelics as potential treatments for illnesses such as depression, anxiety, and PTSD, the newly developed system could offer scientists a new way to produce these compounds for research purposes... [P]rogress in this field remains limited, in part due to regulatory restrictions, underscoring the need for more research. This creates practical challenges for scientists. "Traditionally, the supply of psychedelics relies on natural producers, mainly plants, fungi, and the Sonoran Desert toad," the researchers write. "Harvesting these organisms for their psychoactive compounds raises ecological and ethical concerns, being increasingly threatened by habitat loss and overexploitation..." [T]he team carefully monitored the plant's production of five psychedelic tryptamines: DMT originally from plants; psilocin and psilocybin from mushrooms; and bufotenin and 5-MeO-DMT from toads. The modified tobacco plants were found to produce all five compounds simultaneously. The article points out that the researchers "also took it a step further." By tweaking the enzymes they were able to "produce modified versions of the compounds that do not naturally occur in plants, and which may also have therapeutic value."

Read more of this story at Slashdot.

Longtime Slashdot reader fahrbot-bot writes: CU Boulder researchers are reporting that they have discovered an appetite-suppressing compound in python blood that helps the snakes consume enormous meals and go months without eating yet remain metabolically healthy. The findings were published in the journal Natural Metabolism on March 19, 2026. Pythons can grow as big as a telephone pole, swallow an antelope whole, and go months or even years without eating -- all while maintaining a healthy heart and plenty of muscle mass. In the hours after they eat, research has shown, their heart expands 25% and their metabolism speeds up 4,000-fold to help them digest their meal. The team measured blood samples from ball pythons and Burmese pythons, fed once every 28 days, immediately after they ate a meal. In all, they found 208 metabolites that increased significantly after the pythons ate. One molecule, called para-tyramine-O-sulfate (pTOS) soared 1,000-fold. Further studies, done with Baylor University researchers, showed that when they gave high doses of pTOS to obese or lean mice, it acted on the hypothalamus, the appetite center of the brain, prompting weight loss without causing gastrointestinal problems, muscle loss or declines in energy. The study found that pTOS, which is produced by the snake's gut bacteria, is not present in mice naturally. It is present in human urine at low levels and does increase somewhat after a meal. But because most research is done in mice or rats, pTOS has been overlooked. "We've basically discovered an appetite suppressant that works in mice without some of the side-effects that GLP-1 drugs have," said senior author Leslie Leinwand, a distinguished professor of Molecular, Cellular and Developmental Biology who has been studying pythons in her lab for two decades. Drugs like Ozempic and Wegovy act on the hormone glucagon-like petide-1 (GLP-1).

Read more of this story at Slashdot.

In a new 4,000-word article, CNN tells the story of a retired appellate paralegal and grandmother in her early 70s who was treated for depression with psilocybin. CNN notes there's now retreats featuring psilocybin in a few countries — and while psilocybin is illegal under United States federal law, "In Oregon, 5,935 clients received psilocybin services through Oregon's state-regulated program in 2025." High doses of psilocybin are effective in treating depression, a growing body of research suggests, with promise for other conditions, like PTSD and addiction, said Dr. Albert Garcia-Romeu, associate director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University... Some researchers suggest it disrupts entrenched traffic patterns in the brain or grows new neuron connections to change thinking. Others say the results from psilocybin could have to do with its anti-inflammatory effect, Garcia-Romeu said... Colorado became the second state to make psilocybin legal with a 2023 law and issued its first healing center" last year. A law adopted in New Mexico last year established that state's Medical Psilocybin Program, now in development... Psilocybin seems to be "knocking on the door of FDA approval," said Dr. Lynn Marie Morski, president of the Psychedelic Medicine Association, which educates health care providers on the therapeutic use of psychedelics so they can answer patients' questions through the lenses of clinical evidence and harm reduction. Psilocybin therapy first received a "breakthrough therapy" designation for treatment-resistant depression from the US Food and Drug Administration in 2018, and now psilocybin drug products are on track to be submitted to the FDA for possible approval in the not-too-distant future. While psilocybin is illegal under United States federal law, more states are creating their own paths for legal use under state laws.

Read more of this story at Slashdot.

"A surgeon in London says he has performed the UK's first long-distance robotic operation," reports the BBC, "on a patient located 1,500 miles (2,400km) away..." Leading robotic urological surgeon Professor Prokar Dasgupta said it felt "almost as if I was there" as he carried out a prostate removal on [62-year-old] Paul Buxton... It is hoped that remote robotic surgery could spare future patients the "vast expense and inconvenience" of travelling for treatment, and help deliver better healthcare to people in more remote locations... Buxton had expected to be put on an NHS waiting list after receiving a shock prostate cancer diagnosis just after Christmas, but he "jumped at the chance" to be the first patient to undergo the treatment remotely as part of a trial. "A lot of people actually said to me: 'You're not going to do it, are you?' "I thought, I'm giving something back here," he said... The operation was performed from The London Clinic using a robot equipped with a 3D HD camera and four arms, all controlled through a console with a delay of only 0.06 seconds. The console in the UK was connected to the robot in Gibraltar via fibre-optic cables, with a backup 5G link. A team in Gibraltar remained on standby in case the connection failed, but it held throughout the procedure... Dasgupta will perform the procedure again on 14 March, which will be live-streamed to 20,000 world-leading urological surgeons at the European Association of Urology congress. He added: "I think it is very, very exciting, the humanitarian benefit is going to be significant." The U.K.'s National Health Service "is prioritising local robotic-assisted surgery," the article points out, "aiming for 500,000 robot-supported operations a year by 2035." Thanks to Slashdot reader fjo3 for sharing the article.

Read more of this story at Slashdot.